Eastern Virginia Medical School   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Norfolk VA United States (1973)

Organization Overview

First Clinical Trial
1994
NCT00004430
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CHILDREN'S HOSPITAL OF KING'S DAUGHTERS/EASTERN VIRGINIA MEDICAL SCHOOL | Clinical Research Center, Eastern Virginia Medical Scholl, Norfolk, VA | Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA | CONRAD Clinical Research Center, Eastern VA Medical School | CONRAD Clinical Research Center, Eastern Virginia Medical School | CONRAD Eastern Virginia Medical School | Director, Conrad Clinical Research Center. | Eastern VA Medical School, Norfolk, VA | Eastern Virgina Medical School | Eastern Virginia Medical School | Eastern Virginia Medical School, CONRAD | Eastern Virginia Medical School/CONRAD | Eastern Virginia Medical School department of obstetrics and gynecology | Eastern Virginia Medical School Department of Otolaryngology | Eastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery | Eastern Virginia Medical School (EVMS) | Eastern Virginia Medical School / Norfolk General Hospital | Eastern Virginia Medical School, Strelitz Diabetes Center | Eastern Virginia Medical School- Urology | Eastern Virginia Medical School, VA | Hubbard, Thomas W., M.D. | Intira Sriprasert | Kay I Waud MD PhD | Strelitz Diabetes Center, Eastern Virginia Medical School | Williams, Judith V., M.D.

Active Ingredients

Drugs in Phase 4 Trials (13)

acetylsalicylic acid (aspirin) (1 trial)

bromocriptine (parlodel) (1 trial)

desogestrel (Mercilon) (1 trial)

doxycycline (vibramycin) (1 trial)

esomeprazole (nexium) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

etonogestrel (1 trial)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

icosapent ethyl (vascepa) (1 trial)

levonorgestrel (1 trial)

medroxyprogesterone (provera) (2 trials)

omalizumab (xolair) (1 trial)

pyridostigmine bromide (mestinon) (1 trial)

Drugs in Phase 3 Trials (12)

bupivacaine (Exparel) (1 trial)

dehydroepiandrosterone (4 trials)

enoxaparin (lovenox) (1 trial)

fondaparinux sodium (arixtra) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

letrozole (femara) (1 trial)

mometasone (elocon) (1 trial)

oxybutynin (ditropan) (1 trial)

prasterone (intrarosa) (1 trial)

pregabalin (lyrica) (1 trial)

progesterone (progestasert) (2 trials)

tranexamic acid (cyklokapron) (2 trials)

Drugs in Phase 2 Trials (17)

adalimumab (humira) (1 trial)

apremilast (otezla) (1 trial)

aztreonam (azactam) (1 trial)

cannabidiol (Epidiolex) (1 trial)

celecoxib (celebrex) (1 trial)

emtricitabine (emtriva) (1 trial)

estradiol (progynon depot) (4 trials)

imiquimod (aldara) (1 trial)

inactivated influenza vaccine (1 trial)

liraglutide (victoza) (1 trial)

lisofylline (1 trial)

nonoxynol-9 (Delfen) (1 trial)

pirenzepine (1 trial)

polio, inactivated poliovirus vaccine (Salk Vaccine) (1 trial)

tc-6987 (1 trial)

tenofovir (viread) (3 trials)

tenofovir alafenamide (genvoya) (3 trials)

Drugs in Phase 1 Trials (3)

elvitegravir (vitekta) (2 trials)

oxygen (1 trial)

zb-06 (1 trial)

Drugs in Other Trials (11)

acetylcysteine (mucomyst) (1 trial)

ciclopirox (loprox) (1 trial)

griseofulvin (grisactin) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

ketoconazole (nizoral) (1 trial)

lisinopril (zestril) (1 trial)

metronidazole (flagyl) (1 trial)

nicotine (nicorette) (1 trial)

porfimer (photofrin) (1 trial)

prednisone (meticorten) (1 trial)

selenium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Alzheimer Disease (Phase 2)

Asthma (Phase 4)

Atrophy (Phase 3)

Autonomic Nervous System Diseases (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Cystic Fibrosis (Phase 2)

Dementia (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Neuropathies (Phase 4)

Esophagitis, Peptic (Phase 4)

Fibrosis (Phase 2)

Gastroesophageal Reflux (Phase 4)

Head and Neck Neoplasms (Phase 1)

Hemorrhage (Phase 4)

Hypertriglyceridemia (Phase 4)

Inflammation (Phase 2)

Influenza, Human (Phase 2)

Leiomyoma (Phase 3)

Lichen Planus (Phase 2)

Mucositis (Phase 2)

Myofibroma (Phase 3)

Nasal Polyps (Phase 3)

Nervous System Diseases (Phase 2)

Neuralgia (Phase 3)

Neurocognitive Disorders (Phase 2)

Nose Diseases (Phase 2)

Pain, Postoperative (Phase 3)

Papilloma (Phase 4)

Papillomavirus Infections (Phase 2)

Periodontal Diseases (Phase 4)

Peripheral Nervous System Diseases (Phase 3)

Poliomyelitis (Phase 2)

Polycystic Ovary Syndrome (Phase 3)

Polyneuropathies (Phase 3)

Polyps (Phase 3)

Primary Dysautonomias (Phase 2)

Psychomotor Agitation (Phase 2)

Respiratory Tract Infections (Phase 2)

Sarcoidosis (Phase 2)

Sinusitis (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Sweat Gland Diseases (Phase 2)

Syndrome (Phase 3)

Thromboembolism (Phase 3)

Urethral Stricture (Phase 3)

Uterine Hemorrhage (Phase 3)

Vaginal Diseases (Phase 4)

Vaginitis (Phase 2)

Vaginosis, Bacterial (Phase 4)

Venous Thromboembolism (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial APIs: 56